These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 23389753)

  • 21. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
    Sin JH; Berger K; Lesch CA
    J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversal of direct oral anticoagulants: a practical approach.
    Shih AW; Crowther MA
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):612-619. PubMed ID: 27913536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation.
    Lee HF; Chan YH; Chang SH; Tu HT; Chen SW; Yeh YH; Wu LS; Kuo CF; Kuo CT; See LC
    J Am Heart Assoc; 2019 Mar; 8(5):e011112. PubMed ID: 30834802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [NOAC: Real-life data and the role of antidotes for the treatment of bleeding].
    Darius H
    Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):99-104. PubMed ID: 28144725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of bleeding with oral anticoagulants in patients with atrial fibrillation.
    Bosch J; Eikelboom JW
    Hamostaseologie; 2015; 35(4):351-7. PubMed ID: 26013362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring and reversal strategies for new oral anticoagulants.
    Vanden Daelen S; Peetermans M; Vanassche T; Verhamme P; Vandermeulen E
    Expert Rev Cardiovasc Ther; 2015 Jan; 13(1):95-103. PubMed ID: 25431993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral anticoagulants and status of antidotes for the reversal of bleeding risk.
    Ebright J; Mousa SA
    Clin Appl Thromb Hemost; 2015 Mar; 21(2):105-14. PubMed ID: 25115762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antidotes for novel oral anticoagulants: current status and future potential.
    Crowther M; Crowther MA
    Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1736-45. PubMed ID: 26088576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
    Perzborn E; Heitmeier S; Laux V; Buchmüller A
    Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversal of Novel Anticoagulants in Emergent Surgery and Trauma: A Comprehensive Review and Proposed Management Algorithm.
    Palaiodimos L; Miles J; Kokkinidis DG; Barkolias C; Jonnalagadda AK; Papaconstantinou D; Frountzas M; Misiakos EP; Schizas D
    Curr Pharm Des; 2018; 24(38):4540-4553. PubMed ID: 30585542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prothrombin complex concentrates as reversal agents for new oral anticoagulants: lessons from preclinical studies with Beriplex.
    Dickneite G
    Clin Lab Med; 2014 Sep; 34(3):623-35. PubMed ID: 25168947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Activated Prothrombin Complex Concentrate for Reversal of the Anticoagulant Effect of Apixaban and Rivaroxaban in Patients with Major Bleeding.
    Sheikh-Taha M; Clark HL; Crawley RM
    Clin Drug Investig; 2023 Nov; 43(11):883-888. PubMed ID: 37882941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical perspectives on the management of bleeding in patients on oral anticoagulants: the DECOVER Study (DElphi Consensus on oral COagulation and therapy action reVERsal)].
    Vicente V; Martín A; Lecumberri R; Coll-Vinent B; Suero C; González-Porras JR; Marco P; Mateo J; Roldán V; Soulard S; Crespo C; Camats M;
    Emergencias; 2017 Feb; 29(1):18-26. PubMed ID: 28825264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversal of anticoagulants: an overview of current developments.
    Greinacher A; Thiele T; Selleng K
    Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activated prothrombin complex concentrates for direct oral anticoagulant-associated bleeding or urgent surgery: Hemostatic and thrombotic outcomes.
    Shaw JR; Carrier M; Dowlatshahi D; Chakraborty S; Tokessy M; Buyukdere H; Castellucci LA
    Thromb Res; 2020 Nov; 195():21-28. PubMed ID: 32645667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
    Ragni MV
    Hematology Am Soc Hematol Educ Program; 2013; 2013():44-51. PubMed ID: 24319161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 'New' direct oral anticoagulants in the perioperative setting.
    Breuer G; Weiss DR; Ringwald J
    Curr Opin Anaesthesiol; 2014 Aug; 27(4):409-19. PubMed ID: 24979070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants.
    Dhakal P; Rayamajhi S; Verma V; Gundabolu K; Bhatt VR
    Clin Appl Thromb Hemost; 2017 Jul; 23(5):410-415. PubMed ID: 27789605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversal of antithrombotic agents.
    Bauer KA
    Am J Hematol; 2012 May; 87 Suppl 1():S119-26. PubMed ID: 22460529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.